CLDF Liver Update | Saturday, March 25, 2023
The CLDF Liver Update serves as our accredited plenary session taking place at the Third Annual Liver Connect conference.
Saturday, March 25, from 8:00 AM – 12:15 PM PT
Session III: Hepatitis B & D
Session IV: Controversies in the Management of Cirrhosis
Please select “Register/Take Course” to complete the following:
- Program Evaluation
Upon completion, you will receive your accreditation certificate.
The pre-test will close on Saturday, March 25, at 8:00 AM PT.
The post-program activities will become available on Saturday, March 25, at 12:15 PM PT.
Upon completion of this activity, participants should be able to:
- Describe chronic liver disease (CLD) management recommendations/guidelines for new treatments and describe current guidelines for the diagnosis and management of gastrointestinal (GI) disorders.
- Utilize new therapies and employ an evidence-based approach to the management of GI disorders and optimize treatment results for patients with CLD.
- Identify new advances and assess their potential impact on clinical practice.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Chronic Liver Disease Foundation (CLDF). Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this Live Activity for a maximum of 3.0 AMA PRA Category 1 Credits™ on Friday, March 24, 2023, and 3.75 AMA PRA Category 1 Credits™ on Saturday, March 25, 2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.
All relevant conflicts of interest have been mitigated prior to the start of the activity.
None of the planners, reviewers, CLDF staff, and Purdue University College of Pharmacy staff have a relevant financial relationship(s) with ineligible companies to disclose unless listed below.
This activity is jointly provided by the Purdue University College of Pharmacy and the Chronic Liver Disease Foundation.
This activity is supported by an educational grant from Exelixis, Inc.and Salix Pharmaceuticals.
- 3.75 AMA PRA Category 1 Credit™
- 3.75 AMA PRA Category 1 Credit™ (Non- MD)